Clinical Research Directory
Browse clinical research sites, groups, and studies.
Establishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics.
Sponsor: The First Affiliated Hospital of Guangzhou Medical University
Summary
This study will utilize tissue and peripheral blood samples for metabolomics analysis and establish a longitudinal metabolomics cohort at multiple critical treatment time points to comprehensively investigate the role of metabolomics in the diagnosis, prognosis, and therapeutic monitoring of lung cancer. By profiling metabolic alterations, this study aims to identify potential biomarkers for distinguishing benign and malignant lung nodules, predicting therapeutic efficacy, and assessing long-term prognosis. Key time points include initial screening for lung nodules, postoperative evaluation to predict treatment outcomes, and therapeutic monitoring to assess efficacy after medication or other interventions. Through these analyses, the study seeks to uncover underlying metabolic mechanisms and provide valuable insights into personalized lung cancer management.
Official title: Establishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics to Explore Biomarkers and Therapeutic Mechanisms.
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
OBSERVATIONAL
Enrollment
2500
Start Date
2024-01-01
Completion Date
2027-12-31
Last Updated
2025-02-25
Healthy Volunteers
No
Interventions
Monitoring serum metabolites in lung cancer patients using tissue and peripheral blood samples.
This study focuses on monitoring serum metabolites in lung cancer patients by utilizing tissue and peripheral blood samples. By analyzing the metabolic profiles of serum, the research aims to identify significant metabolic alterations associated with lung cancer progression, treatment response, and overall prognosis. The study seeks to provide a comprehensive understanding of how metabolic changes in serum reflect disease dynamics and therapeutic outcomes, ultimately contributing to the development of more accurate diagnostic and prognostic biomarkers for lung cancer management.
Locations (1)
the First Affiliated of Guangzhou Medical University
Guangzhou, Guangdong, China